JPMorgan Chase & Co. Decreases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

JPMorgan Chase & Co. decreased its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 73.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 37,065 shares of the company's stock after selling 103,426 shares during the period. JPMorgan Chase & Co. owned about 0.06% of Kymera Therapeutics worth $1,491,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Blue Trust Inc. lifted its stake in shares of Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company's stock valued at $25,000 after buying an additional 270 shares in the last quarter. KBC Group NV grew its position in shares of Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company's stock valued at $87,000 after purchasing an additional 752 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Kymera Therapeutics during the 4th quarter valued at $310,000. Arizona State Retirement System lifted its holdings in Kymera Therapeutics by 15.5% during the 4th quarter. Arizona State Retirement System now owns 11,221 shares of the company's stock worth $451,000 after purchasing an additional 1,503 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its stake in Kymera Therapeutics by 35.8% in the 4th quarter. Teacher Retirement System of Texas now owns 11,490 shares of the company's stock worth $462,000 after purchasing an additional 3,026 shares during the period.

Insider Activity

In related news, CFO Bruce N. Jacobs sold 7,035 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares of the company's stock, valued at approximately $6,147,428.70. This represents a 3.37 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Jeremy G. Chadwick sold 1,383 shares of Kymera Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the completion of the transaction, the chief operating officer now directly owns 67,800 shares of the company's stock, valued at $2,064,510. This trade represents a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 10,659 shares of company stock worth $324,567. Insiders own 15.82% of the company's stock.

Analysts Set New Price Targets

KYMR has been the topic of a number of recent analyst reports. Stephens restated an "overweight" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Citigroup started coverage on shares of Kymera Therapeutics in a research report on Thursday, March 13th. They set a "buy" rating and a $52.00 price target for the company. Finally, HC Wainwright increased their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $56.36.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock traded up $0.40 during trading hours on Thursday, reaching $34.67. The stock had a trading volume of 82,087 shares, compared to its average volume of 554,290. The company has a fifty day simple moving average of $29.68 and a 200-day simple moving average of $38.40. Kymera Therapeutics, Inc. has a 52 week low of $19.45 and a 52 week high of $53.27. The stock has a market cap of $2.25 billion, a PE ratio of -14.82 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). The business had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Research analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.